(Photo via Twitter)
Baltimore biotech company PathSensors is looking to enter the Chinese market.
The Inner Harbor–based biotech company is partnering with Radiusen Systems Limited on distribution of its technology, called CANARY. The system uses an immune cell known as a biosensor to detect disease-causing pathogens. It was developed at MIT Lincoln Laboratory to be used to address bioterrorism threats. In China, the company sees uses for mail screening and other biodefense as well as mail screening, food safety in agriculture and diagnosing problems with plants.
We're so excited to announce that we're expanding abroad! Check out this link to learn more: https://t.co/WTS1oE6f9J
— PathSensors, Inc. (@PathSensorsInc) August 28, 2018
“We’ve seen a dramatic increase in Chinese demand for high-tech diagnostic systems,” PathSensors president Ted Olsen said in a statement. “This partnership enables us to reach the Chinese market and deliver the same industry-leading capabilities that our customers are used to in the United States.”
Olsen recently visited Shenzhen-based Radiusen and demonstrated for potential customers in China. The companies plan to develop a manufacturing lab where the biosensors used in PathSensors’ system will be made.
Pathsensors, which has 20 employees, is based at Columbus Center, where it’s part of a cluster of biotech research and startup activity alongside the University System of Maryland’s IMET. The company is eying further international expansion through partnerships with Japan, Europe, Australia, and the Middle East.-30-
Baltimore’s TranZed Apprenticeships brings in tech training from Steve Wozniak’s Woz U
Index Analytics brings tech and talent to partnership with Code in the Schools
This form of art blends science and technology to tell stories through biological products
Get to know SmartLogic’s culture of plants, podcasts and productive client relationships
KaloCyte moves to University of Maryland BioPark
Early Charm Ventures launches Abri Science with $225K in funding
UMB grants licensing option for anticancer drug that uses Anthrax
Entrepreneurs, think it’s too early to engage a legal partner? It’s not.
Sign-up for daily news updates from Technical.ly Baltimore